SERIAL EVALUATION OF SERUM PROTEIN PROFILE FOLLOWING BREAST CANCER TREATMENT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 最近对血液中蛋白质的研究表明，患有乳腺癌的人和没有患乳腺癌的人之间的蛋白质谱发生了微妙的变化。这项临床试验的主要目标是确定乳腺癌患者的血液蛋白是否发生了变化，以及在乳腺癌手术治疗后这种变化需要多长时间才能恢复正常。在未来，这可能是决定癌症分期和乳腺癌治疗效果的一个非常重要的测试。 在这项临床研究中，外科医生或抽血技师将取出血样。根据协议，总共将提取约10至15毫升血液并进行专门处理。这将发生在手术前和手术后2周、4周和每月6个月(总共8个平局)。这项试验的目的是确定血液中蛋白质谱是否存在变化。 这项试验的目标是： 术前确定乳腺癌患者血清蛋白谱中乳腺癌类型的患病率。 测定从癌变型到正常型的血清蛋白质谱正常化的时间进程。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent studies on proteins in blood have demonstrated subtle changes in the protein profile between individuals that do have and individuals that do not have breast cancer. The primary goal of this clinical trial is to determine whether blood proteins are altered in patients with breast cancer and how long it takes for the alteration to normalize following surgical treatment of breast cancer. In the future, this may be a very important test to determine the staging of cancer and the effectiveness of breast cancer treatment. In this clinical study, the surgeon or a blood drawing technician will remove a sample of blood. A total of about 10 to 15 milliliters of blood will be removed and processed specifically per protocol. This will occur before surgery and additionally after surgery at 2 weeks, 4 weeks, and monthly for 6 months after surgery (8 draws in total). The goal of this trial is to determine the presence of changes in the protein profile in blood. The objectives of this trial are: Determine the prevalence of breast cancer type serum protein profile in breast cancer patients prior to surgery. Determine the time course of normalization of serum protein profile from cancer-type to normal-type.